Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
704 (USA) · Dr. Tanaka
consented 2012-11-19
AEs
1
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild BLOOD GLUCOSE INCREASED — outcome: NOT RECOVERED/NOT RESOLVED; onset 2012-12-30 (study day 42.0); relationship: NONE
Data queries
No data queries.